This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kearns, C. M. Articles by Crom, W. R. Search for Related Content PubMed PubMed Citation Articles by Kearns, C. M. Articles by Crom, W. R.

Pharmacokinetics of Cladribine (2-Chlorodeoxyadenosine) in Children with Acute Leukemia¹

Departments of Pharmaceutical Sciences [C. M. K., W. R. C.], Hematology-Oncology [V. M. S.], and Molecular Pharmacology [R. L. B.], St. Jude Children's Research Hospital, and Departments of Clinical Pharmacy [W. R. C.], Pediatrics [V. M. S.], and Pharmacology [R. L. B.], University of Tennessee, Memphis, Tennessee 38101-0318

Cladribine is a synthetic purine nucleoside with demonstrated activity in hairy cell leukemia and acute myeloid leukemia. We have studied the pharmacokinetics of this drug in 25 pediatric patients with acute leukemia treated with cladribine as a single agent, 8.9 mg/m²/24 h, for 5 days by continuous i.v. infusion. Twelve patients were in relapse, and acute myeloid leukemia was newly diagnosed in 13 patients. Plasma, urine, and cerebrospinal fluid cladribine concentrations were determined by a radioimmunoassay with a limit of detection of 1 nM. An open two-compartment model was fit to the plasma concentration data. The mean (SD) clearance was 39.4 (12.4) liters/h/m² and ranged from 14.4–55.4 liters/h/m². When clearance was normalized to body weight (liters/h/kg) it was negatively correlated with age, with older patients having slower clearances per unit of body weight. However, when clearance was normalized to body surface area, no significant correlation with age was observed. The mean (SD) steady-state plasma concentration (predicted 120-h concentration) was 37.7 (17.3) nM and ranged from 23.2–84.5 nM. The terminal phase half-life in 22 patients ranged from 14.3–25.8 h, with a mean (SD) of 19.7 (3.4) h. The volume of distribution at steady state was highly variable, with a mean (SD) of 356.6 (225.2) liters/m². None of these parameters was significantly different between patients in relapse and patients with newly diagnosed disease. Renal clearance was determined in 7 patients and ranged from 34.6–643.6 ml/min/m², with a mean (SD) of 317.9 (208.7) ml/min/m². Renal clearance as a percentage of total systemic clearance ranged from 11.0–85.1%, with a mean of 51.0%. In 11 patients, the mean (SD) cerebrospinal fluid concentration was 6.1 (3.97) nM, a mean of 18.2% of the steady-state plasma concentration. The CSF:plasma concentration ratio was significantly higher on day 5 (22.7% in 7 patients) than on day 4 (7.6% in 3 patients; P = 0.03). Additional studies are needed to further define the metabolic fate of cladribine. In this paper we provide the first comprehensive description of the pharmacokinetics of this drug in children and provide data which suggest that cladribine may be useful in the treatment of patients with meningeal leukemia or malignancies of the central nervous system.

¹ This research was supported by grant FD-R-000349 from the Orphan Products Development Office of the U. S. Food and Drug Administration, grants CA 20180 (Leukemia Program Project) and CA 21765 (Cancer Center CORE Support) from the NIH, a Center of Excellence grant from the State of Tennessee, and by American Lebanese Syrian Associated Charities (ALSAC).

² To whom requests for reprints should be addressed, at Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105.

Received 10/ 5/93. Accepted 12/30/93.

This article has been cited by other articles:

				J. A Brousil, R. J Roberts, and A. L Schlein Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis Ann. Pharmacother., October 1, 2006; 40(10): 1814 - 1821. [Abstract] [Full Text] [PDF]

				S. L. Berg, P. L. Bonate, J. G. Nuchtern, R. Dauser, L. McGuffey, B. Bernacky, and S. M. Blaney Plasma and Cerebrospinal Fluid Pharmacokinetics of Clofarabine in Nonhuman Primates Clin. Cancer Res., August 15, 2005; 11(16): 5981 - 5983. [Abstract] [Full Text] [PDF]

				R. A. Krance, C. A. Hurwitz, D. R. Head, S. C. Raimondi, F. G. Behm, K. R. Crews, D. K. Srivastava, H. Mahmoud, W. M. Roberts, X. Tong, et al. Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases J. Clin. Oncol., June 1, 2001; 19(11): 2804 - 2811. [Abstract] [Full Text] [PDF]

				R. Chen, B. F. Pan, M. Sakurai, and J. A. Nelson A nucleoside-sensitive organic cation transporter in opossum kidney cells Am J Physiol Renal Physiol, February 1, 1999; 276(2): F323 - F328. [Abstract] [Full Text] [PDF]

				A. K Morris, J. M Kolesar, and J. G Kuhn Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 94 - 109. [PDF]

				P. Hentosh and M. Tibudan 2-Chloro-2'-deoxyadenosine, an Antileukemic Drug, Has an Early Effect on Cellular Mitochondrial Function Mol. Pharmacol., April 1, 1997; 51(4): 613 - 619. [Abstract] [Full Text]